140 related articles for article (PubMed ID: 11531830)
1. Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy.
Yoshino T; Asada H; Ando Y; Fujii H; Yamaguchi Y; Yoshikawa K; Itami S
Br J Dermatol; 2001 Sep; 145(3):415-21. PubMed ID: 11531830
[TBL] [Abstract][Full Text] [Related]
2. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X
Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
[TBL] [Abstract][Full Text] [Related]
4. Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone.
Hoffmann R; Wenzel E; Huth A; van der Steen P; Schäufele M; Henninger HP; Happle R
J Invest Dermatol; 1994 Oct; 103(4):530-3. PubMed ID: 7930677
[TBL] [Abstract][Full Text] [Related]
5. Age dependence of diphenylcyclopropenone sensitization in patients with alopecia areata.
Temesvári E; González R; Marschalkó M; Horváth A
Contact Dermatitis; 2004 Jun; 50(6):381-2. PubMed ID: 15274737
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic use of topical contact sensitizers in benign dermatoses.
Buckley DA; Du Vivier AW
Br J Dermatol; 2001 Sep; 145(3):385-405. PubMed ID: 11531828
[TBL] [Abstract][Full Text] [Related]
7. Effects of acute, low-dose UVB radiation on the induction of contact hypersensitivity to diphenylcyclopropenone in man.
Friedli A; Hunziker T; Finkel B; Braathen LR
Arch Dermatol Res; 1993; 285(1-2):1-5. PubMed ID: 7682397
[TBL] [Abstract][Full Text] [Related]
8. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy.
von Moos S; Johansen P; Waeckerle-Men Y; Mohanan D; Senti G; Häffner A; Kündig TM
Allergy; 2012 May; 67(5):638-46. PubMed ID: 22380933
[TBL] [Abstract][Full Text] [Related]
9. Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions.
Bröcker EB; John SM; Steinhausen D; Hamm H
Arch Dermatol Res; 1991; 283(2):133-4. PubMed ID: 2069412
[No Abstract] [Full Text] [Related]
10. Impaired responses of peripheral blood mononuclear cells to nickel in patients with nickel-allergic contact dermatitis and concomitant atopic dermatitis.
Buchvald D; Lundeberg L
Br J Dermatol; 2004 Mar; 150(3):484-92. PubMed ID: 15030331
[TBL] [Abstract][Full Text] [Related]
11. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata.
Happle R; Klein HM; Macher E
Arch Dermatol Res; 1986; 278(3):214-8. PubMed ID: 2873796
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
13. Topical immunotherapy treatment of alopecia areata with diphenylcyclopropenone: Regulatory T cells as biomarkers for treatment response.
Kyrmanidou E; Apalla Z; Koletsa T; Sotiriou E; Ioannides D; Fotiadou C; Chatzopoulos S; Kemanetzi C; Lazaridou E
Dermatol Ther; 2022 Jul; 35(7):e15522. PubMed ID: 35436374
[TBL] [Abstract][Full Text] [Related]
14. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
15. Topical immunotherapy in dermatology.
Buckley DA; du Vivier AW
Int J Clin Pract; 1999 Mar; 53(2):130-7. PubMed ID: 10344049
[TBL] [Abstract][Full Text] [Related]
16. Alopecia areata: topical immunotherapy--application and practical problems.
MacDonald N; Wiseman MC; Shapiro J
J Cutan Med Surg; 1999 Nov; 3 Suppl 3():S36-40. PubMed ID: 11776938
[No Abstract] [Full Text] [Related]
17. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata.
Tobin DJ; Gardner SH; Lindsey NJ; Hoffmann R; Happle R; Freyschmidt-Paul P
Eur J Dermatol; 2002; 12(4):327-34. PubMed ID: 12095876
[TBL] [Abstract][Full Text] [Related]
18. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
Galadari I; Rubaie S; Alkaabi J; Galadari H
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526
[TBL] [Abstract][Full Text] [Related]
19. Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP/OX40L/IL-13 pathway in severe alopecia areata.
Gong Y; Luo L; Li L; He X; Lu W; Sha X; Mao Y
Exp Dermatol; 2021 Feb; 30(2):278-283. PubMed ID: 33325128
[TBL] [Abstract][Full Text] [Related]
20. In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis.
Katagiri K; Arakawa S; Hatano Y
Arch Dermatol Res; 2007 Jan; 298(8):397-401. PubMed ID: 17021766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
